More than 1,200 cases of heart inflammation in adolescents and young adults following Pfizer’s or Moderna’s COVID vaccine have been reported to health authorities in the United States, the Centers for Disease Control and Prevention (CDC) said on June 23.
The bulk of the reports submitted to the Vaccine Adverse Event Reporting System, a passive reporting system run by two top health agencies, dealt with myocarditis or pericarditis experienced after a second dose of a messenger RNA-based COVID-19 vaccine.
Of the 1,226 reports of post-vaccination heart inflammation—a jump from less than 800—827 were for myocarditis or pericarditis after dose two. Another 267 were after a first dose. The rest were reports after an unspecified dose.
Most of the cases were seen after the Pfizer-BioNTech shot. The others were seen after a Moderna shot.
Continuing a trend first seen earlier this year, the majority of the patients were male. About 40 percent were 29 years old or younger.
Of the 323 cases meeting the CDC’s case definition, 309 were hospitalized. Nine are still hospitalized.
The case rate, based on reports to the reporting system, is higher than expected in young males.
For males between the ages of 12 to 17, the expected number of cases following dose one using a 21-day window was two to 21. The observed incidence was 32 through June 11.
For males between the age of 18 and 24, the expected number of cases using the same parameters was three to 34. The observed incidence was 47.
Following dose two using a 21-day window, the observed rate was much higher in males up to 39 years old. It was also higher for females from 12 to 24 years old.
The data were presented by Dr. Tom Shimabukuro, a CDC official, to the agency’s vaccine advisory committee.
This is an excerpt from The Epoch Times.
Scroll down to leave a comment and share your thoughts.